Rapamycin and Low-dose IL-2 Mediate an Immunosuppressive Microenvironment to Inhibit Benign Prostatic Hyperplasia
International Journal of Biological Sciences · 2023
DOI: 10.7150/ijbs.85089 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2023. Verfasst von Tianyu Cao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Prostatic Hyperplasia. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Benign prostatic hyperplasia (BPH) is a condition that becomes more common with age and manifests itself primarily as the expansion of the prostate and surrounding tissues. However, to date, the etiology of BPH remains unclear. In this respect, we performed single-cell RNA sequencing of prostate transition zone tissues from elderly individuals with different prostate volumes to reveal their distinct tissue microenvironment. Ultimately, we demonstrated that a reduced Treg/CD4+ T-cell ratio in the large-volume prostate and a relatively activated immune microenvironment were present, characterized partially by increased expression levels of granzymes, which may promote vascular growth and profibrotic processes and further exacerbate BPH progression. Consistently, we observed that the prostate gland of patients taking immunosuppressive drugs usually remained at a smaller volume. Furthermore, in mouse models, we confirmed that both suppression of the immune system with rapamycin and induction of Treg proliferation with low doses of IL-2 therapy indeed prevented the progression of BPH. Taken together, our findings suggest that an activated immune microenvironment is necessary for prostate volume growth and that Tregs can reverse this immune activation state, thereby inhibiting the progression of BPH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Plastic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Laboratory Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Pathology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Center for Immune-Related Diseases at Shanghai Institute of Immunology, Department of Respiratory and Critical Care Medicine of Ruijin Hospital, Department of Immunology and Microbiology, Shanghai Jiao Tong University S…
Zitieren
APA
Cao, T., Xie, F., Shi, Y., Xu, J., Liu, Y., Cui, D., Zhang, F., Lin, L., Li, W., Gao, Y., Ruan, Y., Wang, X., Zhu, Y., Han, B., Xia, S., Guo, W., Li, B., & Jing, Y. (2023). Rapamycin and Low-dose IL-2 Mediate an Immunosuppressive Microenvironment to Inhibit Benign Prostatic Hyperplasia. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.85089
Vancouver
Cao T, Xie F, Shi Y, Xu J, Liu Y, Cui D, et al. Rapamycin and Low-dose IL-2 Mediate an Immunosuppressive Microenvironment to Inhibit Benign Prostatic Hyperplasia. International Journal of Biological Sciences. 2023. doi:10.7150/ijbs.85089
BibTeX
@article{Cao2023,
author = {Cao, Tianyu and Xie, Feng and Shi, Youwei and Xu, Junhao and Liu, Yi and Cui, Di and Zhang, Fang and Lin, Lihui and Li, Weize and Gao, Yanting and Ruan, Yuan and Wang, Xiaohai and Zhu, Yiping and Han, Bangmin and Xia, Shujie and Guo, Wenhuan and Li, Bin and Jing, Yifeng},
title = {Rapamycin and Low-dose IL-2 Mediate an Immunosuppressive Microenvironment to Inhibit Benign Prostatic Hyperplasia},
journal = {International Journal of Biological Sciences},
year = {2023},
doi = {10.7150/ijbs.85089}
}
EUVIMED